11149 related articles for article (PubMed ID: 1580117)
21. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
Schofield K; D'Aquila T; Rimm DL
Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
[TBL] [Abstract][Full Text] [Related]
22. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
Kobzik L; Antman KH; Warhol MJ
Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
[TBL] [Abstract][Full Text] [Related]
23. Interphase nucleolar organizer regions in the evaluation of serosal cavity effusions.
Carrillo R; Sneige N; el-Naggar AK
Acta Cytol; 1994; 38(3):367-72. PubMed ID: 8191825
[TBL] [Abstract][Full Text] [Related]
24. The cytologic application of carcinoembryonic antigen for the discrimination of malignant from benign serous effusions.
Kyrkou KA; Iatridis SG; Athanassiadou PP; Athanassiadis PP; Mandragos CE
Cancer Detect Prev; 1985; 8(1-2):247-54. PubMed ID: 4064045
[TBL] [Abstract][Full Text] [Related]
25. The cell block for body cavity fluids: do the results justify the cost?
Jonasson JG; Ducatman BS; Wang HH
Mod Pathol; 1990 Nov; 3(6):667-70. PubMed ID: 1702212
[TBL] [Abstract][Full Text] [Related]
26. Malignant effusions: from diagnosis to biology.
Davidson B
Diagn Cytopathol; 2004 Oct; 31(4):246-54. PubMed ID: 15452897
[TBL] [Abstract][Full Text] [Related]
27. [Preparatory techniques of fluids and screening of malignant cells in effusions].
Nagumo S
Rinsho Byori; 1990 Nov; Suppl 87():191-200. PubMed ID: 2287088
[No Abstract] [Full Text] [Related]
28. Morphometric differences between cytologically benign and malignant serous effusions.
Gavin FM; Gray C; Sutton J; Clayden AD; Banks RI; Bird CC
Acta Cytol; 1988; 32(2):175-82. PubMed ID: 2450434
[TBL] [Abstract][Full Text] [Related]
29. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of p53 protein in the study of serous effusions.
Zoppi JA; Pellicer EM; Sundblad AS
Acta Cytol; 1995; 39(4):721-4. PubMed ID: 7631546
[TBL] [Abstract][Full Text] [Related]
31. Cytopathology of exocrine pancreatic carcinoma in effusions.
Di Bonito L; Dudine S; Falconieri G
Acta Cytol; 1991; 35(3):311-4. PubMed ID: 1710404
[TBL] [Abstract][Full Text] [Related]
32. Role of DNA flow cytometry and immunocytochemical analysis in diagnosis of malignant effusions.
Kundu R; Handa U; Mohan H
Diagn Cytopathol; 2012 Oct; 40(10):887-92. PubMed ID: 21485027
[TBL] [Abstract][Full Text] [Related]
33. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R
Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206
[TBL] [Abstract][Full Text] [Related]
34. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
35. The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis.
van de Molengraft FJ; Vooijs GP
Acta Cytol; 1988; 32(2):183-7. PubMed ID: 3348059
[TBL] [Abstract][Full Text] [Related]
36. Subclassification of lymphoproliferative disorders in serous effusions: a 10-year experience.
Tong LC; Ko HM; Saieg MA; Boerner S; Geddie WR; da Cunha Santos G
Cancer Cytopathol; 2013 May; 121(5):261-70. PubMed ID: 23460311
[TBL] [Abstract][Full Text] [Related]
37. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
38. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
[TBL] [Abstract][Full Text] [Related]
39. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
[TBL] [Abstract][Full Text] [Related]
40. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
